Access to data may be provided following review of the application by a scientific review board including independent academic scientists and healthcare professionals.
Eric D Bateman MB ChB (UCT), MD (UCT), FRCP, DCH(UK)
Emeritus Professor
Division of Pulmonology & Department of Medicine
University of Cape Town
And
Knowledge Translation Unit, University of Cape Town Lung Institute
George Street, Mowbray 7700
Cape Town, South Africa
John Villumsen (cand. Stat.)
Independent Statistical Consultant
StatAssist
Denmark
The review process and role of the independent scientific review board is described in the scientific review board charter. Review criteria include general assessment, the patient’s perspective, a scientific perspective and a methodology assessment.
If access to data is granted, you will be given an estimated timeline for data sharing. An independent third party will analyse the data according to the statistical analysis plan and forward the results directly to you.
Applicants must publish the results as stated in the submitted publication plan.
To apply for access to clinical trial data, please complete and submit the research proposal form including CVs and a statistical analysis plan to ClinicalTrials@alk.net.
After successful submission, you will receive a confirmation of receipt and an estimated timeline for handling of your application.
Please note that if you are granted access to data, you will need to sign the data sharing agreement.
If funding and/or approvals are required to perform the research e.g. approvals from ethics committees, it is the responsibility of the applicant to secure this.
Our latest vacancies are continuously updated on our Vacant Positions page.
In 2018, we introduced a set of three Cultural Beliefs to support the cultural transformation of the company: Do the right thing, Pursue growth and Build bridges.
These Cultural Beliefs, which are further clarified through a set of behaviours that are associated with each belief, are intended to inspire and empower our people to do their very best work every day in the pursuit of new and better allergy treatments and solutions for people with allergy around the world.
Our Cultural Beliefs ensure understanding and support for our strategic priorities and the everyday behaviours that will help us to achieve them.
I never thought that I would have an international career
Matteo moved from Italy to Denmark to take on new responsibilities
My name is Matteo Bacchin and I am Global Brand Manager for our Venom portfolio and our emergency product for severe allergic reactions. I have been with ALK since 2009 and recently, I embarked on a new exciting adventure, moving from Italy to Denmark to take on new responsibilities in Global Marketing.
Part of a big family
What I appreciate most about working in ALK is the feeling of being part of a big family where people care for each other and work in a united manner to accomplish goals. It's important not to underestimate the value in having a work environment where colleagues are supportive and share their successes with common pride. For me personally, this family trait has become even more evident now that I'm a foreigner in a new country; the warm welcome and open arms I have met everywhere is overwhelming. It's part of ALK’s DNA.
Moving to a global position
ALK is a company with great potential and a strong focus on growth – both in terms of our geographical expansion, our product portfolio and our employees' strengths and skills. I never thought that I would have an international career. However, when the opportunity presented itself, I took the chance. I'm looking forward to moving from a local to a global position, and I have already realised that having the global responsibility is more complex; you need to have the full picture and adapt a broader perspective on matters. And as for being an Italian in Copenhagen; I'll work on my business English first and next I'll buy a bike and study Danish!
Age: 30 • Nationality: Italian • Education: Master degree in Management Engineering at Politecnico di Milano • Hobbies: Crossfit, running, travelling, reading
I like to see ideas materialise
Maria finds satisfaction in bringing her professional opinion to the table – and being listened to.
My name is Maria Sloth Brendstrup and I am managing the Utility Automation Calibration (UAC) team in Engineering and Production Services in Product Supply. In UAC, we support the production process with technical knowledge and expertise. My main focus is to support and advise our engineers on their daily tasks and priorities and to connect the dots in the communication between the engineers in my team and colleagues in the production with the shared goal of achieving what is the best solution for ALK and our patients.
Input matters
Being a chemist by training and by heart, one of the most rewarding things about working in ALK is the fact that top management listen to professional input and advice from me and my colleagues. It is very satisfying to be able to bring your professional opinion to the table and see ideas materialise because your comments are taken into account and valued as important and relevant input.
Proud of attitude towards compliance
Something I take pride in is our attitude towards compliance and our quality mindset. We have a culture where it's okay to spend time on compliance and to ensure high quality in processes and deliveries. We don't just say that compliance is important because we have to comply with regulations. We walk the talk. We don't think twice about closing the production for a month to fix a compliance cap or improve the quality if that's the right action to take. At the end of the day, we're here to improve quality of life for patients suffering from allergies around the world. Their health is our concern, and we take that responsibility very seriously.
Age: 34 • Nationality: Danish • Education: Cand. Scient. Medicinal Chemistry, University of Aarhus • Hobbies: Two young children, my garden and outdoor fitness all year round
Last updated:
09.11.2016
Owners
Owners
Our owners’ contribution to society
By supporting independent research at the highest level, our owners strive to significantly improve people’s health and well-being.
A stable ownership structure
Although traded on the NASDAQ Copenhagen (OMX: ALK B), ALK boasts an unusually stable ownership, with two shareholders having notified shareholdings of 5% or more.
The Lundbeck Foundation, one of Denmark’s largest enterprise foundations, is the controlling shareholder of ALK, holding 67% of the votes and 40% of the capital. The Foundation grants a minimum of DKK 500 million each year to public biomedical and health science research with a particular focus on neuroscience.
Its business activities encompass majority shareholdings in two other healthcare companies, H. Lundbeck and Falck, a significant shareholding in Ferrosan Medical Devices and Ellab, and an international portfolio of early-stage biotech companies, as well as management of a DKK 20+ billion portfolio of financial investments, primarily in listed securities.
Overview of the Lundbeck Foundation
ALK’s controlling shareholder
The Lundbeck Foundation is the largest and controlling shareholder of ALK, owning 40% of the capital and controlling 67% of the votes.
The Foundation’s commercial activities provide a financial stability that underpins its principal stated aim, that of funding research that aims to reduce the rising global burden of psychiatric and neurological diseases.
The Lundbeck Foundation grants to research a minimum of DKK 500 million each year.
Last updated:
07.08.2023
History
ALK milestones
A history of firsts
For a century, ALK has consistently devised and developed major advances for the treatment of allergy
Since 1923, when pharmacist Peter Barfod and physician Kaj Baagøe documented the first pharmaceutically manufactured allergy preparation, ALK has led the way in allergy treatment, and our long history of ‘firsts’ include demonstrating how to manufacture allergen extracts, establishing a standardised method for large-scale manufacturing, and introducing new, more convenient treatment formulations.
Learn more about our history in our recent book or podcast (Spotify or on Apple Podcasts) covering 100 years of the company’s fascinating developments and innovations.
Explore the history of ALK
June, 1923
ALK's foundation
Doctor Kaj Baagøe and pharmacist Peter Barfod produce Denmark’s first pharmaceutically manufactured allergen extract at Copenhagen University Hospital
June, 1949
Dedicated facilities
Production of allergy immunotherapy treatments and diagnostics is centered at an independent unit called Allergologisk Laboratorium København (Allergology Laboratory Copenhagen)
June, 1972
A new industry standard
ALK develops the technique to accurately identify the proteins that provoke allergies and a standardised process for manufacturing allergen extracts
June, 1978
A world first
The world’s first standardised allergy immunotherapy is launched by ALK
July, 1989
New owner
The Lundbeck Foundation becomes the major shareholder of ALK. The foundation awards research grants primarily to support research in the biomedical sciences
June, 1990
A new treatment option
ALK launches the world’s first sublingual allergy immunotherapy drops (SLIT-drops)
July, 1992
Merger
ALK merges with rival Spanish company Abelló to become ALK-Abelló
July, 2006
First SLIT-tablet
The world’s first sublingual allergy immunotherapy tablet (SLIT-tablet) is approved in Europe.
July, 2008
New logo and name
ALK introduces new logo and changes name to ALK. ALK-Abelló remains the legal name of the company
June, 2017
Inclusion in GINA
For the first time, allergy immunotherapy is recommended as a treatment option in the Global Initiative for Asthma (GINA) strategy document
December, 2017
New transformational growth strategy
ALK launches a new strategy to reach out to more people with allergy and to become a broader-based allergy company
July, 2018
Launch of sister brand
Launch of ALK’s sister brand klarify.me – offering a broad range of pre-screened products and services to help people manage their allergies
January, 2021
Entering food allergies
ALK announces an entry into food allergy treatment and begins developing a tablet for peanut allergies
January, 2023
ALK turns 100 years
We have been pioneers in fighting allergies for 100 years - and we are still counting. Our purpose is to continue helping people with allergies for many years to come.
ALK's foundation
Doctor Kaj Baagøe and pharmacist Peter Barfod produce Denmark’s first pharmaceutically manufactured allergen extract at Copenhagen University Hospital
1923-06-08
Dedicated facilities
Production of allergy immunotherapy treatments and diagnostics is centered at an independent unit called Allergologisk Laboratorium København (Allergology Laboratory Copenhagen)
1949-06-08
A new industry standard
ALK develops the technique to accurately identify the proteins that provoke allergies and a standardised process for manufacturing allergen extracts
1972-06-08
A world first
The world’s first standardised allergy immunotherapy is launched by ALK
1978-06-08
New owner
The Lundbeck Foundation becomes the major shareholder of ALK. The foundation awards research grants primarily to support research in the biomedical sciences
1989-07-01
A new treatment option
ALK launches the world’s first sublingual allergy immunotherapy drops (SLIT-drops)
1990-06-08
Merger
ALK merges with rival Spanish company Abelló to become ALK-Abelló
1992-07-01
First SLIT-tablet
The world’s first sublingual allergy immunotherapy tablet (SLIT-tablet) is approved in Europe.
2006-07-01
New logo and name
ALK introduces new logo and changes name to ALK. ALK-Abelló remains the legal name of the company
2008-07-01
Inclusion in GINA
For the first time, allergy immunotherapy is recommended as a treatment option in the Global Initiative for Asthma (GINA) strategy document
2017-06-01
New transformational growth strategy
ALK launches a new strategy to reach out to more people with allergy and to become a broader-based allergy company
2017-12-04
Launch of sister brand
Launch of ALK’s sister brand klarify.me – offering a broad range of pre-screened products and services to help people manage their allergies
2018-07-03
Entering food allergies
ALK announces an entry into food allergy treatment and begins developing a tablet for peanut allergies
2021-01-03
ALK turns 100 years
We have been pioneers in fighting allergies for 100 years - and we are still counting. Our purpose is to continue helping people with allergies for many years to come.
2023-01-03
ALK's foundation
1923-06-08
Doctor Kaj Baagøe and pharmacist Peter Barfod produce Denmark’s first pharmaceutically manufactured allergen extract at Copenhagen University Hospital
Dedicated facilities
1949-06-08
Production of allergy immunotherapy treatments and diagnostics is centered at an independent unit called Allergologisk Laboratorium København (Allergology Laboratory Copenhagen)
A new industry standard
1972-06-08
ALK develops the technique to accurately identify the proteins that provoke allergies and a standardised process for manufacturing allergen extracts
A world first
1978-06-08
The world’s first standardised allergy immunotherapy is launched by ALK
New owner
1989-07-01
The Lundbeck Foundation becomes the major shareholder of ALK. The foundation awards research grants primarily to support research in the biomedical sciences
A new treatment option
1990-06-08
ALK launches the world’s first sublingual allergy immunotherapy drops (SLIT-drops)
Merger
1992-07-01
ALK merges with rival Spanish company Abelló to become ALK-Abelló
First SLIT-tablet
2006-07-01
The world’s first sublingual allergy immunotherapy tablet (SLIT-tablet) is approved in Europe.
New logo and name
2008-07-01
ALK introduces new logo and changes name to ALK. ALK-Abelló remains the legal name of the company
Inclusion in GINA
2017-06-01
For the first time, allergy immunotherapy is recommended as a treatment option in the Global Initiative for Asthma (GINA) strategy document
New transformational growth strategy
2017-12-04
ALK launches a new strategy to reach out to more people with allergy and to become a broader-based allergy company
Launch of sister brand
2018-07-03
Launch of ALK’s sister brand klarify.me – offering a broad range of pre-screened products and services to help people manage their allergies
Entering food allergies
2021-01-03
ALK announces an entry into food allergy treatment and begins developing a tablet for peanut allergies
ALK turns 100 years
2023-01-03
We have been pioneers in fighting allergies for 100 years - and we are still counting. Our purpose is to continue helping people with allergies for many years to come.
Decades of pushing boundaries and raising standards have placed us at the forefront of our industry, and in recent years, we have invested heavily in gathering unprecedented clinical evidence in support of the latest generation of allergy treatments – sublingual allergy immunotherapy (SLIT) tablets.
When complete, our SLIT-tablet range will cover five of the most common respiratory allergies in the world – house dust mite, grass, trees from the birch tree family, ragweed and Japanese cedar – for all relevant age groups. Our tablets for house dust mite, grass, ragweed and Japanese cedar allergies are already available in many markets and we are working hard to complete the range as quickly as possible.
In 2018, we launched a sister brand klarify.me – offering a broad range of pre-screened drug-free products and services to help people manage their allergies. The overall aim is to transform ALK into a broader-based allergy company that reaches many more people who live with allergy and asthma, and which captures a greater share of the global allergy market by offering solutions for everyone touched by allergy through a comprehensive range of products, services and resources.
From laboratory to global concern
The book about ALK was written in connection with the company's 100 year anniversary in 2023.
The purpose of the book is to give the company's surroundings - current and future employees and its subsidiaries, affiliates, and society as a whole - a thorough understanding of the ALK's history. The book's main author, Professor, Dr. Phil . Kurt Jacobsen from Copenhagen Business School, was given free access to all archives by the company's management.
The book can be freely downloaded, copied and distributed.
ALK’s history dates back to 1923 when the first allergen extracts were produced at the pharmacy of the Copenhagen University Hospital. Since the mid-1980's, international expansion, mergers and acquisitions have helped shape ALK. The company was listed on Nasdaq Copenhagen in 2005.
"14 March 2006 the answer everybody had been waiting for arrived: approval from the swedish authorities of the world's first tablet-based allergy vaccine" (From goose feathers to Grazax, p. 135)
Last updated:
07.06.2023
Global presence
Global presence
Allergy solutions for life
ALK has approximately 2,900 employees, with subsidiaries, production facilities and distributors worldwide.
Addressing a global problem
ALK is present in 46 countries in the world and around 2.4 million people worldwide are using our products
It is estimated that 10-20% of allergic rhinitis sufferers have a condition which is not well controlled despite the use of symptom-relieving medication. ALK's products can potentially benefit these patients.
A global disease House dust mite allergy is the most common respiratory allergy, affecting around half of all people with a respiratory allergy. Furthermore, half of patients with house dust mite allergy suffer from both allergic rhinitis and allergic asthma, which illustrates the need to address both conditions.
At ALK we recognise the impact that living with an allergy that is not well-controlled can have on everyday life. Our commitment is to continue to evolve our products beyond symptom control to give allergy sufferers long-lasting relief with products and solutions that meet the needs of real-life.
Partnerships to leverage growth To deliver on our commitment to patients ALK has entered into partnership agreements with Torii and others to commercialise its latest products in Japan, South-East Asia, Australia and New Zealand, respectively.
More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing.
We have recently added some further detail in our Privacy Statement, making it easier for you to understand what data we collect, how we use it and your rights to manage that information.
If you have any queries please feel free to contact Media Relations at ALK headquarters or one of our global offices.
The press releases in this press room contains information that is of general news value for the press, and available for journalists or media with a view to journalistic assessment and preparation before publication.
